T-cell redirected bispecific antibodies in relapsed and refractory multiple myeloma: A systematic review and meta-analysis.
Syed Hamza Bin Waqar,Razwana Khanam,Mohammad Ebad Ur Rehman,Asmi Chattaraj,Hassam Ali,Faiz Anwer
DOI: https://doi.org/10.1200/jco.2022.40.16_suppl.e20014
IF: 45.3
2022-06-01
Journal of Clinical Oncology
Abstract:e20014 Background: Multiple myeloma (MM) is a malignant plasma cell disorder which remains incurable, and in relapsed and refractory treatment, chimeric antigen receptor therapy shows promise. Bispecific antibodies (bsAbs) utilize the exact mechanism by engaging BCMA and other potential tumor-associated antigens on myeloma cells and T-cells. We have conducted a systematic review and meta-analysis to evaluate the efficacy and safety of bsAbs in heavily pretreated MM cohorts. Methods: We searched PubMed, Clinicaltrials.gov, Cochrane, Google Scholar, Embase, and major conferences (oral and poster presentation), with MeSH terms and keywords for “multiple myeloma” or “relapsed refractory multiple myeloma,” AND “bispecific antibody” or “BiTE”. We included all original studies reported in the English language published from inception until January 2022. After primary and secondary screening, eleven clinical trials were included. Pooled analysis was done with the help of random effects model (Freeman-Tukey Double Arcsine Transformation) in OpenMetaAnalyst software. Results: We identified nine phase I and two phase II trials (n=837), with a mean age of 64.5 years. Most cohorts being triple-, quad- or penta-refractory MM. Complete response (CR) or stringent CR (sCR) reported is 12% (95% CI 9-15.3%, I2 16.54%, n=66), very good partial response (VGPR) 14.8% (95% CI 8.3-22.7%, I2 80.57%, n=93) and partial response (PR) 11.8% (95% CI 0.2-3.41%, I2 93.21%, n=26). The overall response rate (ORR) reported is 59.5% (95% CI 44.7-73.5%, I2 90.71%, n=307). Among the most common adverse events anemia is seen in 44.2% (95% CI 38.1-50.4%, I2 17.86%, n=152), neutropenia in 33.8% (95% CI 18.4-51.2%, I2 93.27%, n=179), thrombocytopenia in 32% (95% CI 21.4-43.6%, I2 75.96%, n=113) and cytokine release syndrome in 57.1% (95% CI 45.5-68.4%, I2 85.63%, n=315). Conclusions: Bispecific antibodies have shown promising efficacy in relapsed and refractory MM cohorts with a very well safety profile. Upcoming phase II/III trials are much awaited, along with combination studies of bsAbs with other agents to gauge response.[Table: see text]
oncology